Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01939548
Recruitment Status : Terminated (A pre-planned interim analysis indicated the trial was unlikely to meet the pre-specified efficacy criteria. The decision was not based on any safety concerns.)
First Posted : September 11, 2013
Results First Posted : August 22, 2016
Last Update Posted : August 22, 2016
Sponsor:
Information provided by (Responsible Party):
Pfizer

Brief Summary:
This study aims to evaluate whether PF-02545920 is safe and effective in the treatment of sub-optimally controlled symptoms of schizophrenia during a 12-week outpatient treatment period. The study will use the Positive and Negative Syndrome Scale (PANSS) to measure change in symptoms for PF-02545920 from baseline compared to placebo.

Condition or disease Intervention/treatment Phase
Schizophrenia Drug: PF-02545920 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 240 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A 12-week , Randomized, Phase 2, Double-blind, Parallel-group Study Of Two Dose Levels Of Pf-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-optimally Controlled Symptoms Of Schizophrenia
Study Start Date : October 2013
Actual Primary Completion Date : October 2014
Actual Study Completion Date : October 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia

Arm Intervention/treatment
Experimental: PF-02545920 (5mg) Drug: PF-02545920
PF-02545920 2 mg BID x 7 days, then 5 mg BID until the Week 12 visit
Other Name: 5 mg BID

Placebo Comparator: Placebo Drug: Placebo
Placebo BID until the Week 12 visit

Experimental: PF-02545920 (15mg) Drug: PF-02545920
PF-02545920 5 mg BID x 7 days, then 10 mg BID x 7 days, then 15 mg BID until the Week 12 visit
Other Name: 15 mg BID




Primary Outcome Measures :
  1. Positive and Negative Syndrome Scale (PANSS) Total Score at Baseline [ Time Frame: Baseline ]
    The Positive and Negative Syndrome Scale (PANSS) assesses the positive symptoms, negative symptoms, and general psychopathology specifically associated with schizophrenia. The scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). The sum of the 30 items is defined as the PANSS Total Score and ranges from 30 to 210; higher score indicates greater severity.

  2. Change From Baseline to Week 12 in PANSS Total Score [ Time Frame: Baseline, Week 12 ]
    The PANSS assesses the positive symptoms, negative symptoms, and general psychopathology specifically associated with schizophrenia. The scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). The sum of the 30 items is defined as the PANSS Total Score and ranges from 30 to 210; higher score indicates greater severity.


Secondary Outcome Measures :
  1. Change From Baseline to Week 12 in Personal and Social Performance Scale (PSP) Total Score [ Time Frame: Baseline, Week 12 ]
    The Personal and Social Performance Scale (PSP) is a validated clinician-related scale that measured personal and social functioning in the domains of: socially useful activities (eg, work and study), personal and social relationships, self-care, disturbing and aggressive behaviors. Information from the participant and the informant were utilized in determining the rating. A PSP total score was determined from the 4 domains (score range 0-100). A score between 71 and 100 indicates a mild degree of difficulty; a score between 31 and 70 indicates a moderate degree of dysfunction, and a participant with a score of 30 or less has functioning so poor he or she requires intensive supervision.

  2. Change From Baseline to Week 12 in PANSS Positive, Negative, and General Subscales [ Time Frame: Baseline, Week 12 ]
    The PANSS includes 3 scales and 30 items: 7 items that make up the Positive Scale (eg, delusions, conceptual disorganization, hallucinatory behavior); 7 items that make up the Negative Scale (eg, blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal); and 16 items that make up the General Psychopathology Scale (eg, somatic concern, anxiety, guilt feelings, mannerisms and posturing, motor retardation, uncooperativeness, disorientation, poor impulse control, preoccupation). Individual items are scored with values ranging from 1 to 7. Total Negative and Positive Subscale scores each range from 7 to 49; higher score indicates greater severity. Total General Psychopathology Subscale score range from 16 to 112; higher score indicates greater severity.

  3. Change From Baseline to Week 12 in PANSS-Derived Marder Factor Scores [ Time Frame: Baseline, Week 12 ]
    The subscales based on Marder factors are: negative symptoms, positive symptoms, disorganized thoughts factor, uncontrolled hostility/excitement factor, and anxiety/depression factor. The symptoms are rated on a 7-point scale, with a range of 7 to 49 for negative symptoms, 8 to 56 for positive symptoms, 7 to 49 for disorganized thoughts and 4 to 28 for uncontrolled hostility/excitement and anxiety/depression. Higher scores indicate higher severity of symptoms.

  4. Change From Baseline to Week 12 in Clinical Global Impression of Severity (CGI-S) [ Time Frame: Baseline, Week 12 ]
    CGI-S: 7-point clinician-rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected. Change: score at observation minus score at baseline.

  5. Clinical Global Impression - Improvement (CGI-I) Total Score at Week 12 [ Time Frame: Week 12 ]
    CGI-I: 7-point clinician-rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected.

  6. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to Adverse Events (AEs) [ Time Frame: Baseline up to 7-10 days after last dose of study drug (follow-up) ]
    An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs comprised both SAEs and non-SAEs. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent adverse events (TEAEs) were defined as newly occurring AEs or those worsening after first dose.

  7. Number of Participants With Change From Baseline and Absolute Values in Vital Signs Meeting Categorical Summarization Criteria [ Time Frame: Screening up to 7-10 days after last dose of study drug (follow-up) ]
    Categorical summarization criteria in vital signs included: sitting, supine, and standing systolic blood pressure (SBP) of less than (<)90 millimeters of mercury (mm Hg) or change in sitting, supine and standing SBP of more than or equal to (>=)30 mm Hg; supine, sitting, and standing diastolic blood pressure (DBP) of <50 mm Hg or change in sitting, supine, and standing DBP of >=20 mm Hg; supine and sitting pulse rate of <40 or more than (>)120 beats per minute (bpm); and standing pulse rate of <40 or >140 bpm.

  8. Number of Participants With Electrocardiogram (ECG) Values Meeting Categorical Summarization Criteria [ Time Frame: Screening/Baseline up to Week 12 (or Early Termination) ]
    Criteria for ECG (12-lead) values meeting categorical summarization criteria were: the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization (PR interval >=300 milliseconds (msec) and increase from baseline >=25/50%; time from the beginning of the electrocardiogram Q wave to the end of the S wave corresponding to ventricular depolarization (QRS) interval >=140 msec and increase of >=50%; the beginning of the Q wave to the end of the T wave corresponding to electrical systole (QT) interval corrected using the Fridericia formula (QTcF) of 450 to <480 msec, 480 to <500 msec and >=500 msec, or an increase of 30 to <60 msec or >=60 msec.

  9. Number of Participants With Weight Change >=7% [ Time Frame: Screening up to Day 84 ]
    The effects of PF-02545920 on body weight were evaluated. The number of participants with changes from baseline in body weight of >=7% were tabulated and summarized.

  10. Number of Participants With New/Intensified Physical Examination Findings From Baseline by Body Site [ Time Frame: Baseline and Week 12 or Early Termination ]
    A complete physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems.

  11. Number of Participants With Laboratory Test Abnormalities [ Time Frame: Screening up to Week 12/Early Termination and 7-10 days after last dose of study drug (hematology only) ]
    Number of participants with laboratory test abnormalities without regard to baseline abnormality. Laboratory test parameters included hematology, liver function, renal function, lipids, electrolytes, hormones (prolactin), clinical chemistry, and urinalysis (dipstick and microscopy).

  12. Number of Participants With Extrapyramidal Motor System (EPS) AEs [ Time Frame: Baseline up to 7-10 days after last dose of study drug (follow-up) ]
    EPS AEs consisted of oromandibular dystonia, extrapyramidal disorder, akathisia, dyskinesia, and tremor.

  13. Change From Baseline in Cholesterol, Triglycerides (TG), Low-Density Lipoprotein (LDL), and High-Density Lipoprotein (HDL) at Weeks 6 and 12 [ Time Frame: Baseline; Weeks 6 and 12 ]
    Choleseterol, TG, glycosylated hemoglobin (HbA1c), LDL, HDL, insulin, and prolactin were a part of the laboratory tests done (metabolic tests).

  14. Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Weeks 6 and 12 [ Time Frame: Baseline; Weeks 6 and 12 ]
    Choleseterol, TG, HbA1c, LDL, HDL, insulin, and prolactin were a part of the laboratory tests done (metabolic tests).

  15. Change From Baseline in Insulin at Weeks 6 and 12 [ Time Frame: Baseline; Weeks 6 and 12 ]
    Choleseterol, TG, HbA1c, LDL, HDL, insulin, and prolactin were a part of the laboratory tests done (metabolic tests).

  16. Change From Baseline in Prolactin at Weeks 6 and 12 [ Time Frame: Baseline; Weeks 6 and 12 ]
    Choleseterol, TG, HbA1c, LDL, HDL, insulin, and prolactin were a part of the laboratory tests done (metabolic tests).

  17. Change From Baseline to Week 12 on the Extrapyramidal Symptom Rating Scale‑Abbreviated (ESRS‑A) [ Time Frame: Baseline, Week 12 ]
    The ESRS-A is a 28-item instrument designed to facilitate standardized observations of parkinsonism, dystonia, dyskinesia, and akathisia. Ratings were determined through a combination of clinical interview and a motor examination. Scores were divided into individual domain scores and clinical global impression scores (CGI-S). Scores started from 0 (normal) to 6 (0 to 8 for CGI-S), with higher scores indicating greater severity.

  18. Absolute Values of Movement Disorder Burden Score - Dystonia (MDBS-D) Over Active Treatment Period [ Time Frame: Active treatment period (Weeks 1 to 12/Early Termination) ]
    The MDBS-D quantified the dystonia burden during the active treatment period. For an individual participant, MDBS-D took into account all treatment-emergent dystonia events and was defined as a combination of the severity of the AE due to dystonia, AE duration, prescribed concomitant medication, and the total number of days the study treatment was received. Scores for the MDBS-D ranged from 0 (no dystonia events) to 4.5, with higher scores indicating greater dystonia burden.

  19. Overall Number of Participants With Positive Responses to Categories on the Columbia Suicide Severity Rating Scale (C-SSRS) [ Time Frame: Baseline up to 7-10 days after last dose of study drug ]
    C-SSRS assessed whether participant experienced the following: completed suicide (Category 1), suicide attempt (Category 2; response of "Yes" on "actual attempt"), preparatory acts toward imminent suicidal behavior (Category 3; "Yes" on "preparatory acts or behavior"), suicidal ideation (Category 4; "Yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent), any suicidal behavior or ideation, self-injurious behavior (Category 7; "Yes" on "Has subject engaged in non-suicidal self-injurious behavior").

  20. Concentration of PF-02545920 and Its Metabolite, PF-01001252 [ Time Frame: Days 14, 28, 42, 56, 70, 84/Early Termination ]
    Pharmacokinetic (PK) samples were collected at varying times relative to drug dosing whenever participants could be scheduled for study visits (sparse PK sampling). Thus, because of the variable time between the last dose and the collection of the PK samples, typical summary PK analyses were not planned or described in the study protocol and are not available. The study protocol analysis section specified that the sparse sampled PK data might be pooled with PK data from previous PF-02545920 clinical studies, however the study results did not support conducting those analyses.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Psychiatrically stable subjects with schizophrenia who have had a suboptimal response to current treatment
  • Evidence of stable schizophrenia symptomatology greater than or equal to 3 months.
  • Subjects must be on a stable medication treatment regimen greater than or equal to 2 months, including concomitant psychotropic medications.

Exclusion Criteria:

  • History of seizures or of a condition with risk of seizures.
  • Subjects with schizophrenia that have not responded at all to current treatment.
  • Pregnant or nursing females, and females of child bearing potential.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01939548


  Show 44 Study Locations
Sponsors and Collaborators
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT01939548     History of Changes
Other Study ID Numbers: A8241019
First Posted: September 11, 2013    Key Record Dates
Results First Posted: August 22, 2016
Last Update Posted: August 22, 2016
Last Verified: July 2016

Keywords provided by Pfizer:
PF-02545920
schizophrenia
outpatient
safety
efficacy
suboptimal response

Additional relevant MeSH terms:
Layout table for MeSH terms
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders